Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference

BEVERLY, MA--(Marketwired - Sep 5, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be presenting Cellceutix at the 16^th Annual Rodman & Renshaw Global Investment Conference, on Tuesday, September 9 at 3:20 PM EDT.

The conference is being held at the Palace Hotel in New York City from September 8 - September 10. The webcast can be listened to live at http://wsw.com/webcast/rrshq24/ctix and thereafter will be archived for 90 days on the Rodman & Renshaw website and archived as well on the Cellceutix website.

"We are very pleased to once again be presenting at the Rodman and Renshaw annual investment conference," said Leo Ehrlich, Chief Executive Officer at Cellceutix. "In a live webcast for institutional and other investors, we will be providing a comprehensive update on Kevetrin and Prurisol clinical trials and our observations of the recently completed Brilacidin ABSSSI Phase 2b trial. In addition we will be announcing significant corporate developments pertaining to our programs in oral mucositis, and antibacterial and antifungal infections."

About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's key antibiotic, Brilacidin, has completed enrollment in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than most currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.